Search

for
Search:

Research

5 / 1000+ results

The Development of Universal Alopecia During Therapy With TNF-α Inhibitors in Patients With Ankylosing Spondylitis: Description of Three Cases

research The development of universal alopecia during therapy with TNF-α inhibitors in patients with ankylosing spondylitis: description of three cases

October 2021 in “Rheumatology Science and Practice”

The article presents three clinical cases of universal alopecia developing during TNF-α inhibitor therapy and discusses possible mechanisms and the role of pro-inflammatory cytokines.

research 448 Combined therapeutic approach: Inhibition of MMP-9 and JAK Signaling Synergistically Prevents Depigmentation in Experimental Vitiligo

November 2025 in “Journal of Investigative Dermatology”

Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.

research Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease

60 citations , September 2013 in “Alimentary Pharmacology & Therapeutics”

This review discusses the dermatological adverse events from immunosuppressive and anti-TNF therapy in IBD, finding increased risks of non-melanoma skin cancer and other skin conditions, and recommends regular cancer screening.

research TNF‐inhibitor associated psoriatic alopecia: Diagnostic utility of sebaceous lobule atrophy

20 citations , March 2017 in “Journal of cutaneous pathology”

This study describes tumor necrosis factor inhibitor-associated psoriatic alopecia, highlighting the distinctive histologic feature of sebaceous lobule atrophy, which is potentially reversible and helps differentiate it from idiopathic psoriatic alopecia.

research Trichorrhexis nodosa: a distinctive presentation after tumour necrosis factor-α inhibitor therapy

10 citations , July 2015 in “Clinical and Experimental Dermatology”

The authors reported a possible association between the use of etanercept and the development of trichorrhexis nodosa, a hair shaft disorder, in a patient without apparent external causes.

View more "tnf-a inhibitor therapy" in research →

Community Join

5 / 10 results

community Prolactin the Cause of Hair Loss? ABS-201 the Cure?

29 upvotes 2 months ago

Prolactin may contribute to hair loss, but targeting its receptor won't cure androgenetic alopecia. ABS-201 could be a useful alternative or adjuvant therapy, similar to JAK inhibitors, but not more effective than HMI-115.

community Rejected for the 2nd time for the VDPHL01 Clinical Trials (believe it or not!)

in Chat 12 upvotes 1 year ago

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

community Finasteride does deplete important nuero-active steroids

11 upvotes 3 years ago

Finasteride can reduce neuroactive steroids, causing side effects like depression, anxiety, and sexual dysfunction. Some users experience persistent symptoms after stopping finasteride, while others use alternative treatments like topical solutions.

community NMN Promotes Cell Proliferation and Hair Growth by Reducing Oxidative Stress

14 upvotes 2 years ago

NMN shows promise in promoting hair growth by reducing oxidative stress and weakening androgens. It may be a beneficial addition to hair loss treatments like Minoxidil and Finasteride.

community Dutasteride actually has different half lives depending on dose

in Research/Science 37 upvotes 1 year ago

Dutasteride's half-life varies with dosage, and lower doses can be effective with fewer side effects compared to finasteride. Some users report different side effects with dutasteride and finasteride, and extreme dosages of dutasteride are unnecessary and potentially harmful.

View more "tnf-a inhibitor therapy" in community →

Learn

2 / 801 results

learn Neem Oil

natural substance from Neem tree with medicinal and pesticidal properties

learn Tofacitinib

a JAK inhibitor for alopecia areata and other autoimmune conditions

What types of hair loss conditions are most commonly associated with tofacitinib use in clinical settings? Published studies link tofacitinib mainly to alopecia areata and its severe variants — as an off-label drug being studied for them, not as a cause of hair loss. The evidence is mostly small, open-label or retrospective, and relapse after stopping is commonly reported.
What are the key limitations and considerations surrounding tofacitinib in hair loss products and therapies? Reported hair regrowth with tofacitinib comes from alopecia areata, an autoimmune condition — mostly from small, non-randomized studies, with relapse common after stopping. There is no good evidence it helps pattern hair loss, and it is not approved for hair loss anywhere.
What is tofacitinib, and why is it discussed in relation to autoimmune-related hair loss such as alopecia areata? Tofacitinib is a prescription JAK inhibitor approved for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis — not for alopecia areata. It is discussed for hair loss because a 2014 case report and a 2016 open-label trial reported regrowth in severe alopecia areata, but that use is off-label, the regrowth relapsed after stopping, and the drug carries an FDA boxed warning.
All 5 questions on Tofacitinib →

View more "tnf-a inhibitor therapy" in learn →

Clinics

6 / 253 results

All 253 clinic results →

Experts

1 / 1 results

24
Hair Loss Specialist
Assoc. Prof. Dr. Therdpong Tempark, MD
Bangkok, Thailand

Assoc. Prof. Dr. Therdpong Tempark, MD